Last reviewed · How we verify
NCT05330936
Comparison of Cyanocobalamin in Avocado Oil Cream With Steroid Combination Ointment
EARLY_PHASE1 trial testing Potent topical steroid in Plaque Psoriasis in 90 participants. Completed in 1 September 2022.
1 September 2022
Quick facts
| Lead sponsor | Pak Emirates Military Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 January 2021 |
| Primary completion | 1 September 2022 |
| Estimated completion | 1 September 2022 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Potent topical steroid — full drug profile →
Conditions studied
- Plaque Psoriasis — all drugs for Plaque Psoriasis →
Sponsor
Pak Emirates Military Hospital
Who can join
Adults 18 to 60, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized clinical trial with two groups. Group A Group B Group A is being treated with conventional Steroid combination ointment for the treatment of chronic Plaque Psoriasis. Group B is being treated with Cyanocobalamin in Avocado Oil cream for the treatment of chronic Plaque Psoriasis. Each group having 45 patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05330936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Plaque Psoriasis
Currently open trials in the same condition.
- NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
- NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
- NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
- NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
- NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting
Other Pak Emirates Military Hospital trials
Trials by the same sponsor.
- NCT07532876 — Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain · Phase 4 · enrolling by invitation
- NCT07294521 — Efficacy of Platelet-rich-Fibrin Gel in Patients With Chronic Leg Ulcers · EARLY_PHASE1 · recruiting
- NCT07508098 — Comparison of Efficacy of Topical Westerhoff Formula Cream Vs Topical 4% Hydroquinone for the Treatment of Melasma · Phase 4 · completed
- NCT06602986 — Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transa · NA · not yet recruiting
- NCT06476366 — Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Contro · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05330936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pak Emirates Military Hospital
- Last refreshed: 24 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05330936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing